No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

PharmaCountry

Home

No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

PharmaCountry

Daily News | Pharmacountry Insights

Home/Insights/Daily News

Daily News

Breaking news and updates from the pharmaceutical industry

#Hutchmed ×

Daily News Market Analysis Research & Reports Regulatory Updates

Daily News

Sep 18, 2026•3 min read

GSK signs up to $1.295B deal for Hutchmed’s KRAS‑EGFR antibody‑drug conjugate HMPL‑A830

GSK will pay $110 million upfront and could invest up to $1.295 billion to secure worldwide rights (excluding China, Hong Kong, Macau, Taiwan) to Hutchmed’s preclinical KRAS‑EGFR ADC, HMPL‑A830, slated for clinical trials later this year.